Two independent, randomised, double-blind, placebo-controlled trials have demonstrated that Lifenol™ effectively manages menopausal symptoms, including hot flashes and sleep disturbances.
A 2023 clinical study – another gold-standard, randomised, double-blind, placebo-controlled trial – has shown that Lifenol™ supports bone health in postmenopausal women with osteopenia.³ Supplementation with 85 mg per day for 48 weeks, along with standard-of-care vitamin D3 and calcium daily supplementation, significantly improved total bone mineral density by 1.8% compared to baseline.³
What’s really interesting is that it increased by 1% compared to supplementation with vitamin D3 and calcium alone. The participants taking Lifenol™ also reported a significant improvement in their physical quality of life and functional health (like participating in vigorous physical activity) compared to placebo.
Based on the strong scientific evidence, Lifenol™ has been awarded health claims in two countries. - The South Korean Ministry of Food and Drug Safety has authorised the health claim on Lifenol™ + Soy extract blend: “May help to maintain female health in menopause.” ⁵ - Health Canada has granted LifenolTM a Natural Product Number and the health claim: “May help relieve menopausal discomforts/complaints.” ⁶
The South Korean Ministry of Food and Drug Safety has authorised the health claim on Lifenol™ + Soy extract blend: “May help to maintain female health in menopause.” ⁵
Health Canada has granted Lifenol™ a Natural Product Number and the health claim: “May help relieve menopausal discomforts/complaints.” ⁶
.svg)
.svg)
.svg)
.svg)
